The one-time gene therapy Itvisma will now be available for people with SMA of all ages in the European Union after winning ...
A study found Evrysdi (risdiplam) helps the body produce more SMN, and also revealed genetic differences between SMA types 2 and 3.
For guest writer Maria Llave, having consistent access to Medicaid provides peace of mind, enabling her to focus on her future.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results